In the high-stakes pharmaceutical and life sciences landscape, a single pricing decision can have massive downstream financial consequences. Yet, too often, pre-deal pricing modeling operates in a silo, completely disconnected from downstream Gross-to-Net (GTN) outcomes. This disconnect leads to margin leakage, unexpected accrual spikes, and a severe lack of deal confidence among leadership.
To win in today’s competitive market, commercial teams must bridge this gap.
Join experts from Argano and Anaplan as they share field-tested best practices for establishing a robust pre-deal modeling framework. You will learn how to design modeling processes that naturally flow into downstream GTN tracking, select the right technology foundation, and apply real-world lessons to avoid common analytical pitfalls.
